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negative symptoms (affective flattening, anhedonia, amotivation, 
attentional impairment, and cognitive impairment) of schizophre-
nia (D’Souza et al., 2004).
LSD anD the Serotonin hypotheSiS
The first drug to attract major attention as a possible model of 
psychosis was LSD. LSD was synthesized in 1938 by Hofmann 
(1980), but its hallucinogenic properties were not discovered till 
Hofmann accidentally spilt some on his skin 5 years later, when he 
recalled later “I happened to experience its unforeseeable effects in 
my own body – or rather, in my own mind,” seeing uninterrupted 
streams of “fantastic pictures, extraordinary shapes with intense 
kaleidoscopic play of colors”.
In the 1960s, the use of LSD and other recreational drugs spread 
among young people across the Western world. Timothy Leary, an 
advocate of psychedelic drugs, was fired from Harvard University, 
where he was a lecturer from 1959 to 1963, and founded the League 
for Spiritual Discovery (L.S.D). His phrase “Turn on, tune in, drop 
out!” became an anthem of the hippie movement. More serious 
individuals such as the famous author, Aldous Huxley also advo-
cated the use of LSD “to make this trivial world sublime,” and even 
took the drug on his deathbed.
Neuropharmacologists began to ask whether schizophrenia 
might be caused by chemical alterations similar to those produced 
by LSD. Shaw and Woolley (1956) hypothesized that LSD might 
act on 5-HT receptors, and later Anden et al. (1968) suggested a 
direct agonist effect at 5-HT receptors in the CNS. The idea that 
the psychotic state induced by LSD resulted from actions at sero-
tonin receptors led to the suggestion that LSD provides a “model 
psychosis” and to the serotonin hypothesis of schizophrenia.
The prevalent view among researchers today is that schizophrenia 
is a syndrome rather than a specific disease. Liability to this syn-
drome is highly heritable but the fact that concordance between 
monozygotic twins is less than 50% suggests an important role for 
environmental influences (Tandon et al., 2008; MacDonald and 
Schulz, 2009). It appears that multiple genetic and environmental 
factors operate together to push individuals over a threshold into 
expressing the characteristic clinical picture (Tsuang et al., 2004; 
Di Forti et al., 2007a).
One environmental factor which has been curiously neglected 
is the evidence that certain drugs can contribute to the onset of 
schizophrenia-like psychosis. Since the mid-twentieth century, 
more knowledge has accumulated concerning this than any other 
causal factor. Here, therefore, we examine the evidence that acute 
administration of drugs such as lysergic acid diethylamide (LSD), 
amphetamines, phencyclidine (PCP), and cannabis can induce psy-
chotic symptoms, and consider the implications for our under-
standing of schizophrenia.
However, before we discuss these issues it is appropriate to 
remind ourselves of a few definitions. The clinical definition of a 
psychotic disorder restricts the term to those illnesses with delusions 
and/or prominent hallucinations, with the hallucinations occurring 
in the absence of insight into their pathological nature (DSM-IV). A 
drug with psychotomimetic actions is one which induces temporary 
states of altered perception (McGraw-Hill, 1993), often mimicking 
the symptoms of psychosis, including delusions, and/or hallucina-
tions (“psychoto-” from psychosis, and “-mimetic” from the Greek 
μιμητιℵος “in imitation of”). Thus, experimental studies examine 
those effects of drugs that resemble the positive symptoms (e.g., 
hallucinations, delusions, paranoia, and disorganized thinking) and 
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One consequence was a great deal of interest in other halluci-
nogens such as N,N-dimethyltryptamine (DMT; Manske, 1931), 
an endogenous substance suspected of being synthesized by the 
pineal gland (Rodriguez, 2007). Szara (1956) gave DMT to healthy 
volunteers and reported hallucinations, distortions of perception 
and body image, speech disturbances, and euphoria. The idea arose 
that schizophrenia might be caused by endogenous hallucinogens, 
and differences in levels of DMT in urine and blood between schizo-
phrenic patients and controls were reported (Franzen and Gross, 
1965; Gillin et al., 1976). Narasimhachari et al. (1972) gave an MAO 
inhibitor (tranylcypromine) and cysteine to both groups and found 
an exacerbation of symptoms and an increase in urinary DMT 
only in schizophrenics. In 1979 one of us (RMM), studying the 
excretion of DMT and its precursor N-methyltryptamine (NMT), 
found a greater DMT excretion in cases of schizophrenia compared 
to controls (Murray et al., 1979); the reasons for these differences 
were never established (Strassman, 1991).
Glennon et al. (1983) proposed the 5-HT2 receptor subtypes as 
the specific target of hallucinogenic drugs such as LSD. Subsequent 
studies in rodents supported this (Nichols, 2004), and investiga-
tions in healthy volunteers provided evidence of 5-HT2A recep-
tor mediation in producing psychotomimetic effects in humans 
(Vollenweider et al., 1998; Carter et al., 2007). The serotonin 
hypothesis received further support from the finding of 5-HT2-
receptor abnormalities in post-mortem schizophrenic brains 
(Mita et al., 1986; Gurevich and Joyce, 1997), but in vivo stud-
ies of 5-HT2-receptor abnormalities reported conflicting results. 
Recently, Rasmussen et al. (2010) assessed 30 antipsychotic-naïve 
schizophrenic patients and matched healthy controls, finding that 
the patients had lower serotonin 2A binding in the frontal cortex. 
Positron emission tomography (PET) scanning in humans showed 
that hallucinogens as psilocybin produced a marked activation of 
the pre-frontal cortex caused by serotonergic (Arora and Meltzer, 
1991; Joyce et al., 1993; Vollenweider et al., 1997). The evidence 
that clozapine is particularly efficacious in the care of treatment 
resistant schizophrenia provoked further interest because of the 
5-HT2 receptor antagonism induced by this drug and other atypical 
antipsychotics (Lieberman et al., 1998; Meltzer, 1999; Tamminga 
and Holcomb, 2005).
Breakey et al. (1974) who investigated the relationship between 
LSD use and the age of onset of schizophrenia commented “On 
the basis of these results it seems plausible to conclude that the 
taking of drugs might play some precipitating role in the onset 
of schizophrenia, bringing this disorder on more quickly.” This 
statement has been amply confirmed. Vardy and Kay (1983), com-
paring patients hospitalized for LSD psychosis with first-break 
schizophrenics, suggested that LSD psychosis was a drug-induced 
schizophreniform reaction; moreover they concluded that there 
was a greater psychotic response to LSD in persons with genetic 
predisposition to schizophrenia.
amphetamine, cryStaL meth, anD the Dopamine theory
As seen in Figure 1, the heyday of research into LSD and other hallu-
cinogens was in the 1960s. However, new laws restricted researchers’ 
ability to study these drugs, and it became clear that LSD produced 
a psychosis with more visual and fewer auditory aberrations than is 
typical of schizophrenia. Interest switched to amphetamines.
The similarity of amphetamine psychosis to schizophrenia 
was first clearly described in the 1950s by Tatetsu et al. (1956) 
and was substantiated by a similar report in Britain from Connell 
(1958) Subsequently, Angrist et al. (1974) found that amphetamine 
administered experimentally produced a picture similar to para-
noid psychosis in healthy individuals and exacerbated psychotic 
symptoms in approximately one-third of schizophrenic patients 
(Lieberman et al., 1987); moreover neuroleptic drugs blocked 
these psychotogenic effects of amphetamines (Espelin and Done, 
1968). Amphetamine was found to stimulate dopamine outflow, 
while, in contrast, antipsychotics were found to block dopamine 
receptors in the brain (Carlsson and Lindqvist, 1963; Van Rossum, 
1967). Subsequently SPET and PET studies demonstrated that acute 
administration of amphetamine induced greater striatal dopamine 
release in first-episode schizophrenia patients compared to healthy 
controls (Laruelle et al., 1996; Breier et al., 1997). Together these 
observations provided the basis for the dopamine hypothesis of 
schizophrenia (Snyder, 1972).
Since the 1990s there has been a marked increase in use of 
methamphetamine (sometimes termed crystal meths) particu-
larly in South-East Asia [United Nations Office on Drugs Crime 
(UNODC), 2009], producing a rapid rise in methamphetamine 
psychosis in the same countries (Chen et al., 2003). In 2003 Chen 
and colleagues recruited 445 amphetamine users from a psychiatric 
hospital and a detention center in Taiwan. One hundred sixty-
three had methamphetamine psychosis which presented a picture 
almost identical to that of paranoid schizophrenia. In most cases 
the symptoms slowly disappeared following cessation of the drug 
but in a proportion they did not remit readily, if ever (Grelotti et al., 
2010). Chen and colleagues subsequently addressed the question of 
why some methamphetamine users became psychotic while others 
appeared to be able to continue their use without major problems. 
Not surprisingly, earlier and greater use of methamphetamine was 
associated with increased risk of psychosis. More interestingly, 
methamphetamine users with a pre-existing psychosis-prone per-
sonality were more likely to develop frank psychosis as were those 
with a greater familial risk. Psychosis-prone personality and fam-
ily history were also associated with a more prolonged psychotic 
episode (Chen et al., 2003).
Recently researchers have looked for genes that may confer a 
vulnerability to psychosis subsequent to methamphetamine use. 
Bousman et al. (2009) reviewed 38 genetic association studies, and 
Figure 1 | Number of published papers (Pub Med) on illicit drugs and 
psychosis.
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acuity (Rosenbaum et al., 1959). Although PCP was removed 
from clinical use in 1965, it became popular as a recreational 
drug as “angel dust.”
Subsequently, ketamine, another glutamate antagonist was 
introduced as an anesthetic, and later reports of ketamine induced 
psychosis started to appear. In 1983 Anis and colleagues showed 
that ketamine and phencyclidine selectively reduce responses of 
central neurons acting at the N-methyl-d-aspartate (NMDA) recep-
tor (Anis et al., 1983; Seeman and Tallerico, 2005). The observation 
that PCP and ketamine are NMDA antagonists together with the 
findings of lower levels of glutamate (by about 50%) in cerebro-
spinal fluid samples from schizophrenic patients compared to 
controls gave rise to the “glutamate hypothesis of schizophrenia” 
(Kim et al., 1980). Although, this latter finding was not consist-
ently replicated, the idea of hypoglutamatergic transmission in 
schizophrenia has continued to attract great interest as has the 
effects of NMDA antagonists (Tamminga and Holcomb, 2005). 
A dissenting view comes from Pomerol and colleagues who gave 
ketamine to 10 healthy volunteers. The commonest feature was 
referential thinking of a delusional nature, together with a range 
of perceptual abnormalities perhaps best described as dissociative. 
However, it did not induce hallucinations, and the authors were 
doubtful about its ability to cause thought disorder; furthermore, 
although negative-like symptoms resulted they could not exclude 
the possibility that this was simply due to its anesthetic effects 
(Pomarol-Clotet et al., 2006).
According to the glutamate deficiency theory, drugs which 
enhance glutamate neurotransmission should improve psychotic 
symptoms. Trials of glutamate potentiation using glycine and related 
compounds have not reported any antipsychotic effects (Deakin 
and Simpson, 1997) but in 2007 Lilly developed LY2140023 which 
is a pro-drug of LY404039, a selective agonist for metabotropic 
glutamate 2/3 (mGlu2/3) receptors. A randomized, three-armed, 
double-blind, placebo-controlled study showed that schizophrenic 
patients treated with LY2140023 improved to a similar extent to 
those treated with olanzapine, both showing greater improvement 
on the positive and negative syndrome scale (PANSS) than placebo 
(Patil et al., 2007). The precise mechanism by which this drug acts 
on schizophrenia is not yet fully understood. However, mGluR2/3 
agonists have been shown to inhibit dopamine release leading to 
the suggestion that dopamine abnormalities in psychosis could be 
secondary to a primary hypofunction in glutamate neurotransmis-
sion (Snyder and Murphy, 2008). Seeman and Tallerico (2005) set 
out to test this last hypothesis, and found that phencyclidine and 
ketamine act on the high affinity state of dopamine D2 receptors 
(dissociation constants of 3 and 55 nM, respectively) suggesting a 
direct or indirect dopamine-mimetic action of phencyclidine.
cannabiS: the SacreD anD ubiquitouS herb
Cannabis is the world’s favorite illicit recreational drug. Its use grew 
in many countries in the latter part of the twentieth century and 
now more than 160 million people take it every day. Within Western 
Europe there have been marked variations in its use (Figure 2) 
with some countries showing a recent decline in the drug’s popu-
larity, e.g., UK, while in others its use continues to grow, e.g., Italy 
[European Monitoring Centre for Drugs, and Drug Addiction 
Annual Report, 2009].
reported four genes associated with psychosis: DTNBP1, which 
codes for dystrobrevin-binding protein 1, OPRM1, which codes 
for the mu-opioid receptor, SNCA, implicated in the modulation 
of dopamine transmission, and a single haplotype of SOD2, which 
encodes a mitochondrial protein important in cellular defense 
against oxidative damage. It remains to be seen how robust these 
associations are.
Generally speaking, amphetamine, and methamphetamine do 
not produce a psychosis after initial use but after repeated use. 
An appropriate theory has to explain this and also why abstinent 
methamphetamine abusers can be precipitated back into a psy-
chosis not only by further methamphetamine abuse by also by 
social stress. One possibility is dopamine sensitization (Ljeberman 
et al., 1990; Glenthøj and Hemmingsen, 1997). In rodents, repeated 
administration of amphetamine leads to reversed tolerance and 
an increased neurochemical and behavioral reaction to each dose. 
Boileau and colleagues tested whether this might happen also in 
humans. They administered dextroamphetamine by mouth on 
days 1, 3, and 5 to 10 healthy volunteers, and measured the effect 
on striatal dopamine release before exposure, then the day of first 
exposure, then 2 weeks later after the third dose, using the PET/
[11C] raclopride technique. Each dose of amphetamine caused 
greater dopamine release in the ventral striatum together with 
greater behavioral responses. Indeed, 1 year later there was a greater 
psychomotor response and greater increase dopamine release com-
pared to the initial dose, in the ventral striatum, progressively 
extending to the dorsal caudate and putamen (Boileau et al., 2006). 
Such findings have led to the “dopamine sensitization” hypothesis 
of schizophrenia which postulates that a sensitized dopamine sys-
tem is responsible for the genesis of psychotic symptoms (Peleg-
Raibstein et al., 2009).
Prolonged methamphetamine abuse may produce permanent 
damage to neurons. Thus, a PET study showed a reduction in 
dopamine transporter density in methamphetamine users, which 
seemed to be related to the duration of methamphetamine use, 
and to the chronic psychotic state in methamphetamine users (Iyo 
et al., 2004).
angeL DuSt provokeS the gLutamate theory
The “dopamine theory” of schizophrenia has dominated attempts 
to explain the positive symptoms seen in schizophrenic patients 
(Kapur and Mamo, 2003) but is less able to account for nega-
tive symptoms. Drugs acting on the glutamate system have been 
proposed to model these. Kotz and Merkel (1926) discovered 
the compound, 1-piperidinocyclohexanecarbonitrile, and thus 
laid the groundwork for the preparation of PCP which was 
developed as an intravenous general anesthetic in the 1940s by 
Parke, Davis & Co. Unfortunately, up to 50% of adult patients 
given PCP developed agitation and hallucinations (Greifenstein 
et al., 1958; Johnstone et al., 1958; Collins et al., 1960), so the 
focus of investigation of PCP shifted from its possible use as 
an anesthetic to its capacity to produce model psychoses (Luby 
et al., 1962). Acute administration of PCP to healthy volunteers 
produced severe disturbances in body image, affect and think-
ing with impressive similarity to “certain primary symptoms of 
the schizophrenic process” (Luby et al., 1959); as well as severe 
impairments of attention, motor function, and proprioceptive 
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study reported a risk for schizophrenia 2.4 times higher among those 
who had used cannabis by 18 years than among non-users. Moreover, 
there was a dose–response relationship in that risk for schizophrenia 
rose to 6.0 times in heavy cannabis smokers (use of cannabis more 
than 50 times at initial interview; Andreasson et al., 1987). After 
15 years of silence, other epidemiological studies on cannabis use and 
schizophrenia started to be published (Arseneault et al., 2002; Van 
Os et al., 2002; Zammit et al., 2002; Fergusson et al., 2003). As sum-
marized in Table 1, today consistent evidence supports an association 
between heavy cannabis use and the risk of psychotic symptoms and 
illness (Green et al., 2005; Henquet et al., 2005; Fergusson et al., 2006; 
Barnett et al., 2007; Di Forti et al., 2007b; Moore et al., 2007; Mc Grath 
et al., 2010) even if the strength and nature of that association is still 
an object of discussion (D’Souza et al., 2004).
Recent meta-analyses reported an increase of the risk between 
1.4 and 1.9 times in people using cannabis that might account for 
8–14% of cases of schizophrenia in different countries (Moore 
et al., 2007). Furthermore, Di Forti et al. (2009) showed a positive 
association between the potency and frequency of cannabis use in 
increasing the risk of psychotic illness.
Delta-9-tetrahydrocannabinol (THC) is the main psychoac-
tive ingredient in cannabis; when given experimentally in suffi-
cient dosage, it can produce transient psychotic symptoms and 
impaired memory via stimulation of CB1 receptors, targets for the 
endogenous cannabinoid [endocannabinoid (eCB)] transmitters 
(Matsuda et al., 1990; Freund et al., 2003; Zuurman et al., 2010). 
Several studies have shown that either pure THC or synthetic CB
1
 
agonists elicit psychotic symptoms in a proportion of healthy vol-
unteers (Leweke et al., 1999a,b; D’Souza et al., 2004; Morrison et al., 
2009; Zuurman et al., 2009). CB1 receptors are widely distributed 
throughout the central nervous system, particularly in the hippoc-
ampus, amygdala, cerebellum, basal ganglia, and pre-frontal cortex 
(Herkenham et al., 1991). They are primarily expressed on gluta-
mate and GABA-ergic terminals (Freund et al., 2003; Chevaleyre 
et al., 2006), and upon stimulation by cannabinoids, act to reduce 
pre-synaptic glutamate or GABA release (Chevaleyre et al., 2006). 
The glutamate and GABA inputs to the band of dopamine neurons 
Cannabis has been linked to the development of psychotic 
symptoms since time immemorial. The world’s oldest pharma-
copeia, the Pen-Ts’ao Chin, traditionally attributed to the Chinese 
Emperor Shen Nung (2737 a.c.), suggests cannabis use as a remedy 
for rheumatic pain, intestinal constipation, disorders of the female 
reproductive system, and malaria, but adds that “if taken in excess 
will produce visions of devils … over a long term, it makes one com-
municate with spirits and lightens one’s body…” (Zuardi, 2006). In 
the mid-nineteenth century the French psychiatrist Moreau de Tour 
noted the phenomenological similarities between drug-induced 
states and psychosis. Indeed, he proposed the use of hashish to 
study madness a full century before the LSD model of psychosis 
(Beringer, 1927; Hofmann, 1980).
The first convincing evidence that cannabis might be a risk factor 
for psychosis came from the Swedish Conscripts Study on in which 
45,570 inductees into the military were followed-up for 15 years. This 
Figure 2 | Trends in the prevalence of “cannabis use in the last year” 
among young adults. Annual Report, 2009.
Table 1 | Studies suggesting an association between cannabis use and psychosis.
Study N Design Prevalence/use Outcome Adjusted risk 
   of cannabis
Andreasson et al. (1987) 45,570 Longitudinal conscript >50 times Hospitalization  2.3 
  cohort (Sweden)
Arseneault et al. (2002) 759 Prospective birth Lifetime Any schizophreniform  3.1 
  cohort (Dunedin)  Disorders
Van Os et al. (2002) 4095 Longitudinal population-based Lifetime Any psychotic symptom 2.8 
  (Netherlands)
Fergusson et al. (2003) 1011 Birth cohort (Christchurch) DSM-IV dependence Any psychotic symptom 1.8
Zammit et al. (2002) 50,087 Longitudinal conscript >50 times Hospitalization 3.1 
  cohort (Sweden)
Henquet et al. (2005) 3467 Prospective cohort Lifetime Any psychotic symptom 1.7 
  (Germany)
Di Forti et al. (2009) 280 Case–control (UK) Lifetime  First-episode psychosis 6.8 
     (skunk users)
Mc Grath et al. (2010) 3801 Prospective cohort (Australia) ≥6 years duration  Non-affective psychosis 2.1
Frontiers in Behavioral Neuroscience www.frontiersin.org January 2011 | Volume 5 | Article 1 | 4
Paparelli et al. Drug-induced psychosis in schizophrenia research
because THC “enters” the pathway at a point which is distal to D2 
receptors. In contrast pharmacological manipulations at CB1 would 
be predicted to impact upon stimulant (D2 initiated), psychosis, 
since CB1 is downstream of D2. Several lines of evidence suggest 
that this might be the case.
It is clear that stimulant sensitization or adaptations to repeated 
drug administration as opposed to single drug exposures, are 
important for the emergence of psychosis. One of the outcomes of 
repeated stimulant administration is a functional up-regulation of 
striatal CB1 receptors (Centonze et al., 2007). Furthermore, several 
recent studies have shown that either CB1 knockout or blockade of 
CB1 receptors by potent CB1 antagonists impairs stimulant sensi-
tization (Corbille et al., 2007; Thiemann et al., 2008a,b). In a par-
ticularly elegant design it was demonstrated that microinjections of 
a potent CB1 antagonist directly into the ventral striatum reduced 
the expression of behavioral sensitization to methamphetamine 
(Chiang and Chen, 2007). Findings with the first generation CB1 
blocker rimonabant in sensitization paradigms have been inconsist-
ent (Lesscher et al., 2005; Thiemann et al., 2008b), but rimonabant, 
as opposed to newer CB1 antagonists, only partially blocks the 
effects of THC in humans (Huestis et al., 2001; Zuurman et al., 2010) 
which might explain why an early trial of rimonabant in schizo-
phrenia failed (Meltzer et al., 2004). Rimonabant is also ineffective 
in animal models of cocaine reward, in contrast to CB1 antagonists 
such as AM251 (Gardiner, personal communication).
Another cannabinoid manipulation has shown more promise. 
The molecule cannabidiol (CBD), a constituent of free-growing, 
natural Cannabis sativa (but largely eliminated from high potency 
cannabis preparations such as skunk; Potter et al., 2008) appears 
to have antipsychotic properties in humans (Leweke et al., 2000; 
Zuardi et al., 2009). At low doses, the receptor pharmacology 
of CBD involves pharmacological antagonism of CB1 agonists 
(despite low affinity for the orthosteric site of CB1 receptors) and 
inhibition of adenosine re-uptake. CBD also inhibits the degrada-
tion of the endocannabinoid molecule anandamide and acts at a 
“third” cannabis receptor termed GPR55 (Pertwee, 2007). CBD 
displays efficacy against stimulant (Zuardi et al., 1991; Moreira and 
Guimaraes, 2005) and NMDA models of psychosis in animals (Long 
et al., 2006), and against l-DOPA (Zuardi et al., 2009), ketamine 
(Bosi et al., 2003), and THC elicited psychosis in humans (Zuardi 
et al., 1982; Bhattacharyya et al., 2009). A single head-to-head trial 
of CBD vs amisulpride in 42 schizophrenic patients found equiva-
lent efficacy (Leweke, 2007), but further data, particularly over the 
longer term, is required before we can definitely conclude that these 
antipsychotic effects are real.
Overall, the above suggests a model in which pharmacologi-
cal manipulations to neurochemical systems controlling traf-
fic through striatal circuits can be either pro- or antipsychotic. 
The most notable feature is the consistency of the pharmacology 
with which facilitating the D2 → eCB → CB
1
 axis appears to be 
 pro-psychotic.
concLuSion
We have seen that a great deal of knowledge has accumulated con-
cerning drug-induced psychoses over the last 50 years. However, 
the picture presenting in the clinic, as opposed to that seen in the 
experimental setting, has not been widely acknowledged as  telling 
in the ventral midbrain express CB
1
 receptors and numerous animal 
studies have shown that exogenous cannabinoids alter the balance 
of excitation and inhibition reaching dopamine cells (Lupica and 
Riegel, 2005; Matyas et al., 2008). Although a net inhibition of 
dopamine cells has been described (Melis et al., 2004), by far the 
most commonly documented effect is an increase in firing with 
attendant elevations of dopamine release at downstream forebrain 
territories (Lupica and Riegel, 2005).
One testable hypothesis which arises is whether the psychoto-
mimetic properties of THC in humans are mediated via excess 
dopamine release. Bossong et al. (2009) used a dopamine D
2
/D
3
 
receptor tracer (raclopride) and positron emission tomography, 
to examine striatal synaptic dopamine release. The tracer binding 
was significantly reduced in the ventral striatum and the precom-
missural dorsal putamen after inhalation of THC compared to 
placebo, implying an increased release of endogenous dopamine 
in these regions. However, the increase is modest compared to that 
obtained with amphetamine and cocaine, and two other studies 
have failed to find such clear-cut results (Stokes et al., 2009). For 
example, another PET study by Stokes et al. (2009) found only 
a non-significant increase in dopamine release in the striatum 
following oral THC. Later Stokes et al. (2010) re-analyzed their 
initial data and showed significant decreases in cortical [11C]-raclo-
pride binding potential after administration of THC, suggesting 
dopamine release in the cortex. Our own group observed clear 
psychotic phenomena (including thought-echo and passivity) in 
a group of 10 healthy volunteers given IV THC during SPET scan-
ning but there were no significant differences in DA release between 
THC and placebo sessions, nor were positive symptoms and DA 
release related (Barkus et al., 2010). Furthermore, D’Souza et al. 
(2005, 2008) showed that D2 blockers did not offer “protection” 
against acute THC-psychosis, either in healthy controls or in stable 
schizophrenic patients. However, the validity of this interpretation 
needs to be investigated and whether the psychotomimetic proper-
ties of THC arise by way of downstream dopaminergic events is 
 currently unclear.
Indeed, the reverse may be true. One of the downstream effects 
of stimulating D2 receptors in the striatum is the synthesis and 
release of endocannabinoid transmitters (Giuffrida et al., 1999; 
Centonze et al., 2004; Kreitzer and Malenka, 2005; Yin and Lovinger, 
2006; D’Souza et al., 2008; Stokes et al., 2010) at the dendritic spines 
of medium spiny neurons (MSNs; Uchigashima et al., 2007). In 
turn, eCBs act in a so-called retrograde fashion to inhibit neighbor-
ing GABA and glutamate terminals (Gerdeman et al., 2002; Robbe 
et al., 2002; Freiman et al., 2006; Adermark et al., 2009). There is 
accumulating evidence that a number of key physiological processes 
within the striatum depend upon D2 → eCB → CB
1
 signaling and 
the subsequent modification of fast amino-acid based transmission 
(Calabresi et al., 2007; Kreitzer and Malenka, 2008). Such processes 
are believed to be vital for the selection and initiation of psychomo-
tor behaviors and for associative learning, or in other words, the 
normal functions of the striatum in health (Graybiel, 2005; Yin and 
Knowlton, 2006; Houk et al., 2007; Kreitzer and Malenka, 2007). 
One question which arises is whether the pro-psychotic effects 
of not just THC, but stimulant drugs as well involve the striatal 
D2 → eCB → CB
1
 trans-synaptic pathway. If this were the case then 
it might explain why D2 blockade has little effect on THC-psychosis 
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